IS5155A - Fjölgervingur af zópólrestat mónóhýdrati - Google Patents

Fjölgervingur af zópólrestat mónóhýdrati

Info

Publication number
IS5155A
IS5155A IS5155A IS5155A IS5155A IS 5155 A IS5155 A IS 5155A IS 5155 A IS5155 A IS 5155A IS 5155 A IS5155 A IS 5155A IS 5155 A IS5155 A IS 5155A
Authority
IS
Iceland
Prior art keywords
zopololestat
monohydrate
multiple copolymers
copolymers
zopololestat monohydrate
Prior art date
Application number
IS5155A
Other languages
English (en)
Inventor
Francis Lambert John
Norris Timothy
Original Assignee
Pfizer Product Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Product Inc. filed Critical Pfizer Product Inc.
Publication of IS5155A publication Critical patent/IS5155A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS5155A 1998-08-21 1999-08-17 Fjölgervingur af zópólrestat mónóhýdrati IS5155A (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9747498P 1998-08-21 1998-08-21

Publications (1)

Publication Number Publication Date
IS5155A true IS5155A (is) 2000-02-22

Family

ID=22263562

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5155A IS5155A (is) 1998-08-21 1999-08-17 Fjölgervingur af zópólrestat mónóhýdrati

Country Status (31)

Country Link
US (1) US6159976A (is)
EP (1) EP0982306A3 (is)
JP (1) JP2000072769A (is)
KR (1) KR20000017411A (is)
CN (1) CN1245804A (is)
AP (1) AP9901662A0 (is)
AU (1) AU4453299A (is)
BG (1) BG103674A (is)
BR (1) BR9903873A (is)
CA (1) CA2280590A1 (is)
EA (1) EA199900675A3 (is)
EE (1) EE9900385A (is)
GT (1) GT199900137A (is)
HR (1) HRP990259A2 (is)
HU (1) HUP9902783A3 (is)
ID (1) ID23307A (is)
IL (1) IL131419A0 (is)
IS (1) IS5155A (is)
MA (1) MA26678A1 (is)
NO (1) NO994027L (is)
NZ (1) NZ337363A (is)
OA (1) OA11150A (is)
PA (1) PA8480601A1 (is)
PE (1) PE20000993A1 (is)
PL (1) PL335016A1 (is)
SG (1) SG83147A1 (is)
TN (1) TNSN99159A1 (is)
TR (1) TR199901996A2 (is)
UY (1) UY25668A1 (is)
YU (1) YU39899A (is)
ZA (1) ZA995297B (is)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3597650T3 (da) 2010-07-16 2022-11-21 Univ Columbia Aldosereduktasehæmmere og anvendelser deraf
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
US20140228319A1 (en) * 2013-02-13 2014-08-14 Banavara L. Mylari Water soluble salts of aldose reductase inhibitors for treatment of diabetic complications
NZ748506A (en) 2016-06-21 2025-07-25 Univ Columbia Aldose reductase inhibitors and methods of use thereof
IL272246B1 (en) 2017-07-28 2025-09-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
SG11202110590PA (en) 2019-04-01 2021-10-28 Applied Therapeutics Inc Inhibitors of aldose reductase
AU2020268368A1 (en) 2019-05-07 2022-01-06 Ucl Business Ltd Treatment and detection of inherited neuropathies and associated disorders
WO2021202523A1 (en) 2020-03-31 2021-10-07 Applied Therapeutics, Inc. Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
JP2023524504A (ja) 2020-05-01 2023-06-12 アプライド セラピューティクス, インコーポレイテッド ソルビトールデヒドロゲナーゼ欠乏症を処置するためのアルドースレダクターゼ阻害剤
EP4211136B1 (en) * 2020-09-08 2025-08-20 Assia Chemical Industries Ltd. Solid state forms of at-001 and process for preparation thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4748280A (en) * 1985-11-07 1988-05-31 Pfizer Inc. Certain chlorination process for preparing 2-chloro-1,1,1-(C1 -C6)
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
JPH0676391B2 (ja) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
US4904782A (en) * 1988-02-29 1990-02-27 Pfizer Inc. Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate
US4954629A (en) * 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
WO1992003432A1 (en) * 1990-08-28 1992-03-05 Pfizer Inc. 3-(5-trifluoromethylbenzothiazol-2-ylmethyl)-4-oxo-3h-phythalazin-1-ylacetic acid monohydrate
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
US6127367A (en) * 1996-02-29 2000-10-03 Pfizer, Inc. Method of reducing tissue damage associated with non-cardiac ischemia

Also Published As

Publication number Publication date
SG83147A1 (en) 2001-09-18
ZA995297B (en) 2001-02-19
HUP9902783A2 (hu) 2000-12-28
PE20000993A1 (es) 2000-10-04
EP0982306A2 (en) 2000-03-01
PL335016A1 (en) 2000-02-28
KR20000017411A (ko) 2000-03-25
NZ337363A (en) 2001-01-26
BG103674A (en) 2000-03-31
AU4453299A (en) 2000-03-09
ID23307A (id) 2000-04-05
CN1245804A (zh) 2000-03-01
BR9903873A (pt) 2000-09-19
EP0982306A3 (en) 2000-07-05
GT199900137A (es) 2001-02-09
NO994027L (no) 2000-02-22
JP2000072769A (ja) 2000-03-07
UY25668A1 (es) 2001-08-27
TR199901996A2 (xx) 2000-03-21
EA199900675A2 (ru) 2000-02-28
AP9901662A0 (en) 1999-09-30
HRP990259A2 (en) 2000-06-30
YU39899A (sh) 2002-12-10
OA11150A (en) 2003-04-16
CA2280590A1 (en) 2000-02-21
EE9900385A (et) 2000-04-17
US6159976A (en) 2000-12-12
HUP9902783A3 (en) 2001-01-29
EA199900675A3 (ru) 2000-06-26
TNSN99159A1 (fr) 2005-11-10
IL131419A0 (en) 2001-01-28
PA8480601A1 (es) 2000-09-29
HU9902783D0 (en) 1999-10-28
NO994027D0 (no) 1999-08-20
MA26678A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
DK1064298T3 (da) Inhibitorer af caspaser
DK1046068T3 (da) Belægning af polymerer
NO990113D0 (no) Flerskrog-fart°y
DE60018219D1 (de) Fluorcopolymere
DE69910832D1 (de) Hochverzweigte blockcopolymere
DK1107980T3 (da) Krystallinske former af EtO2C-CH2-(R)Cgl-Aze-Pab-OH
EE05547B1 (et) Kristalliline efavirens
IT1301451B1 (it) Copolimeri del clorotrifluoroetilene
DE69903524D1 (de) Pestizide hilfsmittel
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
IS5155A (is) Fjölgervingur af zópólrestat mónóhýdrati
FI982335L (fi) Pakettikytkentäiset verkot
DK1155050T3 (da) Fremstilling af polyolefin
ATE273300T1 (de) Elitriptan hydrobromid monohydrat
DE19981163T1 (de) Propylen-Ethylen Blockcopolymere
ID28032A (id) TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2
ATE218388T1 (de) Tray
FI980222A0 (fi) Stycke av isoleringsaemne med en genomgaoende primaerstroemledning
IS5821A (is) Kristalluð form af ósanetant
DE69920704D1 (de) Polyolefinherstellung
NO20015531D0 (no) Mikrobedrepende kopolymerer
DE59909114D1 (de) Armschiene
DE69911356D1 (de) Regale
DK1088010T3 (da) Fremstilling af polyolefiner
FI980856A0 (fi) Andningsskydd utrustad med en identifierare